ODAC Casts 11 to 0 Vote in Favor of Cilta-Cel in R/R Multiple Myeloma
ODAC voted on the risk/benefit ratio of cilta-cel vs standard of care for patients with lenalidomide-refractory multiple myeloma.
ODAC voted on the risk/benefit ratio of cilta-cel vs standard of care for patients with lenalidomide-refractory multiple myeloma.
A new ESMO webinar series where oncology experts discuss and critically evaluate notable recent publications with an aim to enhance understanding and ap…
Supportive Care in Cancer – To investigate the association of food insecurity with overall and disease-specific mortality among US cancer survivors. Data from the National…
New research suggests that mice base their decisions on more than just immediate reward. They may also make ‘mistakes’ on purpose.
Characterization of microbiome genomes at the species level in over 4,000 metastatic tumor biopsies identifies the distribution and diversity features of tumor-resident bacterial DNA at…
Oreo vs Statin Paper: https://www.mdpi.com/2218-1989/14/1/73 Oreo vs Statin Video Abstract: https://youtu.be/L1mMnnyJrgkResponse to Layne on Lipid Energy: ht…
There’s no one-size-fits-all way to prevent dementia, but a key nutrient found in salmon, sesame seeds, walnuts, and more can help keep your brain sharp…
#communicationskills#breakingbadnews#cancer#oncology
Diagnosing genetic disorders requires extensive manual curation and interpretation of candidate variants, a labor-intensive task even for trained geneticists. Although artificial intelligence (AI) …
This review critically analyzes the incidence of trastuzumab-induced left ventricular systolic dysfunction and congestive heart failure (CHF), distinguishing between cases with and without prior anthracycline…